In today’s recent session, 0.63 million shares of the Marinus Pharmaceuticals Inc (NASDAQ:MRNS) have been traded, and its beta is 1.13. Most recently the company’s share price was $1.37, and it changed around $0.04 or 3.01% from the last close, which brings the market valuation of the company to $75.25M. MRNS at last check was trading at a discount to its 52-week high of $11.26, offering almost -721.9% off that amount. The share price’s 52-week low was $1.11, which indicates that the recent value has risen by an impressive 18.98% since then. We note from Marinus Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 2.22 million.
Marinus Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.55. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended MRNS as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) trade information
Instantly MRNS has been showing a green trend so far today with a performance of 3.01% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently down -87.40% year-to-date, but still down -6.48% over the last five days. On the other hand, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) is 6.20% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $4.67, which translates to bulls needing to increase their stock price by 70.66% from its current value. Analyst projections state that MRNS is forecast to be at a low of $2 and a high of $9.
Marinus Pharmaceuticals Inc (MRNS) estimates and forecasts
Marinus Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -85.25 percent over the past six months and at a 28.90% annual growth rate that is well above the industry average of 13.30%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 6.04%. Marinus Pharmaceuticals Inc earnings are expected to increase by 25.30% in 2024, but the outlook is positive 20.00% per year for the next five years.
MRNS Dividends
Marinus Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in July.
